D926PC00001

Research code: D926PC00001
Research name: Open-label, randomized Phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) versus investigator's choice chemotherapy in patients not candidates for PD-1/PD-L1 inhibitor therapy in first-line treatment of locally recurrent, unresectable or metastatic triple-negative cancer breasts (TROPION Breast02).
Indication: breast cancer
Principal researcher: Ewa Chmielowska, MD
Research population: patients with triple-negative breast cancer after recurrence
Research drug: datopotamab deruxtecan